According to Nova one advisor, the global Erectile Dysfunction (ED) Drugs market size is expected to hit around USD 4.40 billion by 2030 from valued at USD 2.50 billion in 2021 and growing at a CAGR of 8.11% from 2022 to 2030.
The increasing prevalence of erectile dysfunction is expected to contribute to market growth. According to the European Association of Urology, the overall prevalence of ED was found to be around 52% in the European male population aged 40-70 years in 2020. In addition, according to the Boston University School of Medicine, approximately 22.9% of 40 years aged male population and 49.4% by age of 70 years are affected by erectile dysfunction. Thus, the increasing geriatric population is anticipated to increase the prevalence of ED over the forecast period and is expected to create lucrative growth opportunities in the market.
Eli Lilly and Company is supporting ED patients by offering medicine at low cost through Lilly Patient Support Program (LPSP). This program provides financial assistance to eligible ED uninsured patients in Canada who may require registration for this program. Thus, the presence of such supportive programs for a branded version of Cialis may increase the affordability of the lower-income patient population and also aid in generating increased revenue. Moreover, companies have undertaken initiatives such as collaboration and partnership for the manufacturing and commercialization of products in the overseas market. For instance, in January 2022, Petros Pharmaceuticals Inc. partnered with a global Contract Manufacturing Organization (CDMO) for the commercial production of Avanafil tablets. This partnership was formed with an aim to replace the existing agreement with Vivus Inc. and continue product supply.
Furthermore, according to the National Library of Medicine (2021), a phase 3 clinical trial was conducted by Sichuan Haisco Pharmaceutical Co., Ltd. to evaluate the safety and efficacy of Stendra in patients with ED in mainland China. The results of the clinical trial showed improvement in Chinese ED patients after administration of two doses of Stendra 100 mg & 200 mg. Such proven clinical effectiveness may strengthen Strenda’s (Avanafil) position in the market. However, lack of awareness about erectile dysfunction, shame about treatment, false-positive beliefs, social stigma pertaining to the disease, and lack of discretion may restrain the market growth. As per the survey conducted by the European Association of Urology (EAU), only 18% of the Spanish population heard about ED treatment, whereas 68.0% of the population believes the treatment benefits.
Report Scope of the Erectile Dysfunction (ED) Drugs Market
|
Report Coverage
|
Details
|
|
Market Size
|
USD 4.40 Billion by 2030
|
|
Growth Rate
|
CAGR of 8.11% from 2022 to 2030
|
|
Largest Market
|
North America
|
|
Fastest Growing Market
|
Asia Pacific
|
|
Base Year
|
2021
|
|
Forecast Period
|
2022 to 2030
|
|
Segments Covered
|
Drug, Distribution Channel And Region
|
|
Companies Mentioned
|
· Pfizer Inc.
· Eli Lilly and Company
· Teva Pharmaceutical Industries Ltd
· Sanofi
· Sun Pharmaceutical Industries Ltd
· Bayer AG
· Petros Pharmaceuticals, Inc.
· VIVUS, Inc.
· Auxilium Pharmaceuticals, Inc.
· Adamed
|
Increase in Awareness and Patient Education: Key Driver
- Educating patients on the appropriate use of erectile dysfunction drugs can be effective through initial education and focusing on the method of administration of drugs. For instance, sildenafil and vardenafil should be taken an hour before intercourse, and food and alcohol intake should be avoided, thereby maintaining the speed and extent of drug absorption. Both the drugs are active for four to six hours. Tadalafil has an advantage of long duration of action i.e., for up to 36 hours. The absorption of tadalafil is unaffected by food and alcohol and the intake of tadalafil is advised several hours before sexual activity. Moreover, adequate sexual stimulation, ideally with a partner, is required.
- Promotional and awareness campaigns for ED drugs should be extensively conducted to help minimize the stigma of impotence by bringing it out onto open discussion forums
- Companies are working on educating the general population and people at risk, and advocating lifestyle changes
- Pharmacists assess the needs of patients and identify drug problems to manage medication therapy
Narrowing of Insurance Coverage for Erectile Dysfunction Treatment
- Development of pharmaceutical and branded drugs incurs large investments and longer duration of time in R&D activities and making them available to the patients for the treatment
- Modifications in the healthcare insurance coverage can significantly affect the drug market. If an insurance program changes its policies and removes coverage for a certain treatment, sales of related drugs are likely to decrease. In general, insurance programs are more likely to cover essential expenses, such as heart disease medication, and are less likely to cover nonessential expenses, such as cosmetic surgery. The type of treatment prescribed for erectile dysfunction decides the possibility of insurance coverage. A person with a documented medical condition responsible for the cause of erectile dysfunction could incur insurance benefits. However, sex therapies and medications that have not been approved by the FDA have not been covered under insurance.
- Due to low dynamic nature, the trend of switching to new drugs or automatic substitution is not prevalent in the erectile dysfunction drugs market, thereby creating further hurdles for players willing to enter the market
Regional Insights
North America dominated the erectile dysfunction drugs market and accounted for a revenue share of 52.2% in 2021 due to the high burden of disease, strong healthcare infrastructure, and approval of new products for treatment. In March 2022, Lupin received the U.S. FDA approval for its ANDA for sildenafil (10 mg/mL oral suspension) to market a generic equivalent to Revatio of Viatris Specialty LLC. The accessibility of affordable generic products may increase patient compliance, consequently, increasing the consumer base and revenue for the market
In Asia Pacific, the market for erectile dysfunction drugs is expected to witness fast growth during the forecast period. The growth of the region is attributable to the entry of new products into the region. For instance, in May 2020, iX Biopharma announced the supply of Wafesil and Silcap through telemedicine in Australia for the treatment of an adult patient with erectile dysfunction.
Erectile Dysfunction (ED) Drugs Market: Key Developments
- Key players in the global erectile dysfunction (ED) drugs market are expanding their market position by adopting various strategies such as mergers & acquisitions and research collaborations with other companies to launch innovative products and consolidate their market positions across the world. A few expansion strategies adopted by players operating in the global erectile dysfunction (ED) drugs market are:
- In December 2020, Glenmark Pharma received the final approval from the U.S. health regulator for Tadalafil tablets, which are used to treat erectile dysfunction and enlarged prostate
- In June 2020, Launch Medical and GAINSWave announced the resolution of their lawsuit and started working together to market their revolutionary home-use acoustic wave device called The Phoenix for the treatment of erectile dysfunction
- The report on the global erectile dysfunction (ED) drugs market discusses individual strategies, followed by company profiles of manufacturers of medical device technology products. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global erectile dysfunction (ED) drugs market.
Some of the prominent players in the Erectile Dysfunction (ED) Drugs Market include:
- Pfizer Inc.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd
- Sanofi
- Sun Pharmaceutical Industries Ltd
- Bayer AG
- Petros Pharmaceuticals, Inc.
- VIVUS, Inc.
- Auxilium Pharmaceuticals, Inc.
- Adamed
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Erectile Dysfunction (ED) Drugs market
- Drug
- Viagra
- Cialis
- Staxyn/Levitra
- Stendra/Spedra
- Others
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Regional Outlook
North America
Europe
- Germany
- France
- United Kingdom
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Erectile Dysfunction (ED) Drugs industry analysis from 2022 to 2030 to identify the prevailing Erectile Dysfunction (ED) Drugs industry opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the global Erectile Dysfunction (ED) Drugs industry segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global Erectile Dysfunction (ED) Drugs industry trends, key players, market segments, application areas, and market growth strategies.
Erectile Dysfunction (ED) Drugs Market